Navigation Links
Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
Date:6/6/2009

NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today new, positive Phase II study results of LY2189265, its investigational glucagon-like peptide 1 (GLP-1) analog administered subcutaneously once-weekly for the treatment of type 2 diabetes. These data will be presented as part of the American Diabetes Association's (ADA) 69th Annual Scientific Sessions.

In the Phase II study, known as GBCJ, LY2189265 was significantly superior to placebo in reducing key measures of glycemic control, including fasting serum glucose and hemoglobin A1C (HbA1C). In this study, LY2189265 showed an insulinotropic (stimulating the secretion of insulin) effect, suggesting it produced the desired outcome in participants. In Study GBCJ, LY2189265 was generally well-tolerated.

"We are excited about these data and the hope they could provide to the millions of diabetes patients who are struggling to maintain tight control of their blood glucose," said Pawel Fludzinski, Ph.D., global development leader for the GLP-1Fc team. "Evaluating the results of this study is an important step forward towards potentially bringing this innovative treatment to patients."

About Study GBCJ

In a 16-week, Phase II study of LY2189265, 262 patients with type 2 diabetes who were suboptimally controlled on at least two oral diabetes medicines were randomized to one of four arms: 1.0 mg of LY2189265 for 16 weeks; 0.5 mg of LY2189265 for four weeks followed by 1.0 mg for 12 weeks; and 1.0 mg of LY2189265 for four weeks followed by 2.0 mg for 12 weeks or placebo. The primary endpoint was glycemic control, as measured by change from baseline in HbA1C; additional endpoints evaluated included changes in fasting serum glucose, solid mixed meal glucose excursion and body weight.

For all do
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... March 31, 2013, before market on Tuesday, May 28, 2013.  ... 28, 2013, at 8:00 a.m. EDT (May 28, 2013 at ... results and provide an update on recent corporate developments. ...
(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
(Date:5/16/2013)...  PTC Therapeutics, Inc., today announced that it has ... U.S. Securities and Exchange Commission ("SEC") relating to the ... number of shares to be offered and the price ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) J.P. ... managers for the offering. Cowen and Company is acting ...
Breaking Medicine Technology:Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... Mich., Jan. 23, 2012 Perrigo Company (Nasdaq: PRGO;TASE) announced ... Administration (FDA) an Abbreviated New Drug Application (ANDA) for azelastine ... the owner of the New Drug Application (NDA) of its ... Impax Laboratories, Inc. (Nasdaq: IPXL ), who will ...
... (OTC: PLCSF), a company focused on innovative medical device ... in the CIN-RG trial, the company,s pivotal trial to ... System™ in the prevention of Contrast-Induced Nephropathy (CIN).  This ... regulatory approval by the U.S. Food and Drug Administration ...
Cached Medicine Technology:Perrigo Confirms Filing for Generic Version of Astepro® Nasal Spray and Announcement of Patent Infringement Lawsuit by Meda Pharmaceuticals 2Perrigo Confirms Filing for Generic Version of Astepro® Nasal Spray and Announcement of Patent Infringement Lawsuit by Meda Pharmaceuticals 3First Patient Treated in PLC Systems' RenalGuard® U.S. Pivotal Trial 2First Patient Treated in PLC Systems' RenalGuard® U.S. Pivotal Trial 3
(Date:5/20/2013)... Goodman HealthDay Reporter , , SATURDAY, May 18 ... a better view during colonoscopies may help them miss ... shows. Colonoscopies are the recommended screening tests for ... of men and women in the United States. ... tube with a camera mounted on the end called ...
(Date:5/20/2013)... May 20, 2013 A novel service for ... . The company has been in the field of providing ... will make sure that scholars are able to maintain a ... has three stages and has been priced at $1000. , ... dedicated mentor assigned to the project, who will handle all ...
(Date:5/20/2013)... Hiscall Inc. is pleased to announce the ... devices. The Hiscall app includes past, current and future ... and event alerts. , For many, the mobile ... such as the Hiscall Technology Showcase, enabling users to register ... layout. During and after the event users can access ...
(Date:5/20/2013)... Dana R. Hando knows that nails ... experience in a salon, she has seen nails of different shapes, ... article that explains how this small body part can actually serve ... body. A piece from The Huffington Post explains that ... on early warning signs of medical conditions. , Nails that ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 When developing ... gender and personality, are taken into consideration to help ... Researchers have previously determined that there is a clear ... Doc considers the science behind these studies and others ... Now, a new study exploring the effect weight gain ...
Breaking Medicine News(10 mins):Health News:New Device May Show Doctors More of the Colon 2Health News:New Device May Show Doctors More of the Colon 3Health News:Dissertation Clinic Prescribes Customized Remedy for Researchers 2Health News:According to Dana R. Hando, Nails Help to Illustrate Total Body Health 2Health News:According to Dana R. Hando, Nails Help to Illustrate Total Body Health 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New Improved hCG Diet Helping Patient’s Control Eating Impulses 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New Improved hCG Diet Helping Patient’s Control Eating Impulses 3
... ... be conducting a lecture on Radiation Therapy Options For Patients Suffering From Mesothelioma. Her lecture ... ... lecture on Tuesday November 10th, 2009, 5:30 pm CST, MesoCare.org is sponsoring a lecture ...
... SHENZHEN, China, Nov. 6 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited ... of medical devices worldwide, today announced that it will ... Trade Fair with,Congress in Dusseldorf, Germany from November 18-21, ... more than 40 devices from its three core product,segments: ...
... Amex: CVM ), a developer of vaccines and therapeutics ... late-stage oncology company, announced today that an Institutional Review Board ... has given clearance for the Company,s first clinical study to ... study, which will be led by Principal Investigator Jonathan M. ...
... for better motor skills later, study suggests, , THURSDAY, ... of oxygen at birth often go on to have ... can help prevent problems. , Now, a new study ... brain lesions in the babies. , Oxygen starvation ...
... America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord ... ) focused on bringing the life saving potential ... nationwide and internationally, today addressed shareholder questions about its ... S1 with the SEC, in an interview of Matthew ...
... ... almost anyone to sustain life in the first critical minutes of cardiac arrest. ... vital organs alive until professional rescuers arrive. AED (Automated External Defibrillator) is an ... to a normal heartbeat. AEDs are very accurate and easy to use. With ...
Cached Medicine News:Health News:Mindray Medical to Exhibit at MEDICA 2009 in Dusseldorf, Germany 2Health News:CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine 2Health News:CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine 3Health News:Cord Blood America Updates Advantages of Las Vegas Laboratory in Analyst Interview; Explains Recent S1 Filing 2Health News:A New Era of E-Learning in the Comfort and Convenience of Your Home or Office Without the Classroom Environment 2
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
... in interbody fusion are to ... restore disc space height and ... an enviroment for bone fusion ... Allograft is designed to promote ...
... highly adaptable and therefore suitable for a ... its extraordinary small outer diameter and the ... a simple but secure and reliable fixation ... instruments around the corner. These characteristics make ...
A new flexible endoscope with an ultra dense optic fiber system. Its two working and irrigation channels and steering mechanism makes it ideal for a multipurpose use in neurosurgical endoscopy i.e. V...
Medicine Products: